| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HER3; FERLK; LCCS2; VSCN1; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ERBB3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ERBB3抗体的3篇代表性文献及其摘要内容：
1. **文献名称**：*"Antitumor activity of a novel anti-ERBB3 antibody in tumors driven by heregulin or ERBB3 overexpression"*
**作者**：Hsieh AC et al.
**摘要**：该研究开发了一种人源化抗ERBB3单抗(MM-121)，通过阻断ERBB3与heregulin结合，抑制下游PI3K/AKT信号通路，在多种ERBB3过表达或heregulin驱动的肿瘤模型中表现出显著的抗增殖和促凋亡活性。
2. **文献名称**：*"ERBB3 overexpression as a therapeutic target in HER2-amplified breast cancer"*
**作者**：Garrett JT et al.
**摘要**：研究发现，在HER2过表达的乳腺癌中，ERBB3的活化是HER2靶向治疗耐药的关键机制。使用抗ERBB3抗体可阻断HER2/ERBB3异源二聚化，恢复肿瘤对曲妥珠单抗的敏感性，并在临床前模型中显著抑制肿瘤生长。
3. **文献名称**：*"Therapeutic targeting of ERBB3 with MM-121 in combination with chemotherapy in preclinical models of lung cancer"*
**作者**：Schoeberl B et al.
**摘要**：研究评估了抗ERBB3抗体MM-121与化疗药物(如紫杉醇)联用的效果。结果显示，MM-121通过抑制ERBB3信号通路，增强化疗药物对肺癌细胞的杀伤作用，尤其在heregulin高表达的肿瘤中效果更显著。
以上文献均聚焦于ERBB3抗体的作用机制及在肿瘤治疗中的应用潜力。
ERBB3 (also known as HER3) is a member of the ERBB receptor tyrosine kinase family, which includes EGFR (HER1), HER2. and HER4. Unlike other family members, ERBB3 has impaired kinase activity due to structural variations in its kinase domain, necessitating heterodimerization with other ERBB receptors (e.g., HER2) for downstream signaling. ERBB3 plays a critical role in regulating cell proliferation, survival, and differentiation via activation of key pathways like PI3K/AKT and MAPK. Its overexpression or aberrant activation is implicated in various cancers, including breast, lung, and colorectal, often contributing to tumor progression, metastasis, and resistance to targeted therapies (e.g., EGFR or HER2 inhibitors).
ERBB3-targeted antibodies are designed to block these oncogenic signals. Monoclonal antibodies (e.g., patritumab, seribantumab) bind to ERBB3’s extracellular domain, preventing ligand binding (e.g., neuregulins) or receptor dimerization, thereby inhibiting downstream signaling. Some antibodies also promote receptor internalization and degradation. Additionally, antibody-drug conjugates (ADCs) and bispecific antibodies (targeting ERBB3 and other ERBB members) are under investigation to enhance therapeutic efficacy. Challenges include identifying predictive biomarkers and overcoming compensatory signaling mechanisms. Clinical trials have shown mixed results, highlighting the need for patient stratification and combination strategies. Overall, ERBB3 antibodies represent a promising approach to tackle resistance in ERBB-driven cancers.
×
